Maryland Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $14.1M | Sell |
105,285
-695
| -0.7% | -$99.7K | 1.18% | 24 |
|
|
2022
Q2 | $16.2M | Sell |
105,980
-2,009
| -2% | -$307K | 1.28% | 24 |
|
|
2022
Q1 | $17.5M | Sell |
107,989
-1,970
| -2% | -$286K | 1.1% | 27 |
|
|
2021
Q4 | $14.9M | Buy |
109,959
+1,758
| +2% | +$208K | 0.81% | 31 |
|
|
2021
Q3 | $11.7M | Buy |
108,201
+7,680
| +8% | +$878K | 0.7% | 34 |
|
|
2021
Q2 | $11.3M | Buy |
100,521
+3,615
| +4% | +$407K | 0.68% | 37 |
|
|
2021
Q1 | $10.5M | Buy |
96,906
+4,204
| +5% | +$450K | 0.7% | 36 |
|
|
2020
Q4 | $9.93M | Buy |
92,702
+9,539
| +11% | +$917K | 0.7% | 33 |
|
|
2020
Q3 | $7.28M | Buy |
83,163
+1,877
| +2% | +$177K | 0.6% | 42 |
|
|
2020
Q2 | $7.98M | Buy |
81,286
+4,949
| +6% | +$436K | 0.74% | 34 |
|
|
2020
Q1 | $5.82M | Buy |
76,337
+11,723
| +18% | +$999K | 0.69% | 45 |
|
|
2019
Q4 | $5.72M | Buy |
64,614
+1,406
| +2% | +$117K | 0.61% | 44 |
|
|
2019
Q3 | $4.79M | Buy |
63,208
+2,074
| +3% | +$142K | 0.55% | 50 |
|
|
2019
Q2 | $4.45M | Buy |
61,134
+5,217
| +9% | +$410K | 0.53% | 50 |
|
|
2019
Q1 | $4.51M | Buy |
55,917
+4,301
| +8% | +$352K | 0.56% | 48 |
|
|
2018
Q4 | $4.76M | Buy |
51,616
+1,987
| +4% | +$175K | 0.69% | 41 |
|
|
2018
Q3 | $4.69M | Buy |
49,629
+1,421
| +3% | +$135K | 0.61% | 41 |
|
|
2018
Q2 | $4.47M | Sell |
48,208
-481
| -1% | -$47K | 0.62% | 42 |
|
|
2018
Q1 | $4.61M | Sell |
48,689
-6,817
| -12% | -$749K | 0.66% | 38 |
|
|
2017
Q4 | $5.37M | Sell |
55,506
-2,250
| -4% | -$212K | 0.79% | 34 |
|
|
2017
Q3 | $5.13M | Sell |
57,756
-479
| -0.8% | -$36.5K | 0.79% | 35 |
|
|
2017
Q2 | $4.22M | Buy |
58,235
+1,395
| +2% | +$93.8K | 0.61% | 41 |
|
|
2017
Q1 | $3.7M | Buy |
56,840
+700
| +1% | +$44K | 0.55% | 43 |
|
|
2016
Q4 | $3.52M | Buy |
56,140
+7,935
| +16% | +$484K | 0.54% | 45 |
|
|
2016
Q3 | $3.04M | Buy |
48,205
+5,840
| +14% | +$378K | 0.46% | 48 |
|
|
2016
Q2 | $2.62M | Buy |
42,365
+6,500
| +18% | +$396K | 0.41% | 49 |
|
|
2016
Q1 | $2.05M | Buy |
35,865
+5,885
| +20% | +$328K | 0.29% | 59 |
|
|
2015
Q4 | $1.78M | Buy |
29,980
+3,100
| +12% | +$179K | 0.26% | 61 |
|
|
2015
Q3 | $1.46M | Buy |
26,880
+2,693
| +11% | +$175K | 0.25% | 65 |
|
|
2015
Q2 | $1.63M | Buy |
24,187
+1,797
| +8% | +$117K | 0.25% | 64 |
|
|
2015
Q1 | $1.31M | Buy |
22,390
+3,905
| +21% | +$236K | 0.2% | 72 |
|
|
2014
Q4 | $1.21M | Sell |
18,485
-600
| -3% | -$37.8K | 0.2% | 75 |
|
|
2014
Q3 | $1.1M | Hold |
19,085
| – | – | 0.19% | 80 |
|
|
2014
Q2 | $1.08M | Sell |
19,085
-420
| -2% | -$22K | 0.19% | 81 |
|
|
2014
Q1 | $1M | Sell |
19,505
-2,900
| -13% | -$147K | 0.18% | 82 |
|
|
2013
Q4 | $1.18M | Sell |
22,405
-2,920
| -12% | -$144K | 0.19% | 84 |
|
|
2013
Q3 | $1.13M | Sell |
25,325
-500
| -2% | -$22.2K | 0.18% | 86 |
|
|
2013
Q2 | $1.07M | Buy |
+25,825
| New | +$1.13M | 0.19% | 87 |
|
Other funds holding ABBV
Maryland Capital Management's ABBV Position: Q3 2022 in Review
Maryland Capital Management reduced its AbbVie (ABBV) stake by 0.66% in Q3 2022, selling an estimated $99.7K and leaving 105,285 shares worth $14.1M. The position accounts for 1.18% of the portfolio, ranked #24.
Maryland Capital Management first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $17.5M in Q1 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- Maryland Capital Management held 105,285 shares of AbbVie worth $14.1M as of Q3 2022.
- Maryland Capital Management sold 695 AbbVie shares in Q3 2022, an estimated $99.7K.
- AbbVie made up 1.18% of Maryland Capital Management's portfolio in Q3 2022, its #24 holding.
- Maryland Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Maryland Capital Management's AbbVie position peaked at $17.5M in Q1 2022.
- 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on Maryland Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.